Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals — Investor Presentation (September 2016)

27 slides from Opiant Pharmaceuticals's investor presentation, Sep 13, 2016

  1. Slide 1: Treatments for Substance Abuse, Addictive and Eating Disorders

    TREATMENTS FOR SUBSTANCE ABUSE, ADDICTIVE AND EATING DISORDERS Corporate Presentation September 2016 OPNT

  2. Slide 2: Forward looking statement

    This presentation contains forward - looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achieveme

  3. Slide 3: Opiant is a specialty pharma company focused on substance use, addictive and eating disorders

    3 Opiant is a specialty pharma company focused on substance use, addictive and eating disorders » Highly capable management team, pioneering the development of NARCAN ® Nasal Spray , that went from concept to approval in under 3 years. » Only FDA approved naloxone nasal spray for opioid licensed to

  4. Slide 4: Substance use, addictive and eating disorders are a significant burden

    Substance u se , addictive and eating disorders are a s ignificant b urden on health in the U.S. 4 Alcohol use disorder Bulimia/Anorexia/ other eating disorder Binge eating disorder Gambling disorder Opioid use disorder Cocaine use disorder 45+ MILLION 17M 12M 8M 2 - 8M 2.4M 1.5M

  5. Slide 5: Need for effective treatments for substance use, addictive and eating disorders

    5 For patients with substance u se , a ddictive and eating d isorders there is a need for effective t reatments Significant burden to the economy Need for new safe and effective treatments Compelling cost savings with effective treatments Few recently approved drugs Annual cost of substance use in t

  6. Slide 6: A common neural circuitry is responsible for substance use, addictive and eating disorders

    6 A common neural circuitry is responsible for substance use, addictive and eating disorders NAc = Nucleus Accumbens GABA = Aminobutyric Acid VTA = Ventral Tegmental Area DA = Dopamine Opioids enhance dopamine release directly and indirectly Reward Circuitry

  7. Slide 7: Opioid antagonists block the reward circuitry in the brain

    O pioid antagonists block the reward circuitry in the brain 7 The Addicted Brain

  8. Slide 8: Opioid antagonists validated as therapeutics with an excellent safety profile

    8 Opioid antagonists have been validated as therapeutics with an excellent safety profile

  9. Slide 9: Opiant aims to become a leading pharma company focused on addiction

    Opiant aims to become a leading p harma c ompany focused on addiction, substance u se and eating d isorders 9 Replicate recent success Enter Larger Market opportunities Invest long term Deliver on first program • More programs expected, with the potential for filing NDAs within 3 years at relatively

  10. Slide 10: Opiant's pipeline well positioned to replicate NARCAN Nasal Spray success

    Opiant’s pipeline well positioned to replicate NARCAN® Nasal Spray success 10 Opioid Overdose OPNT001 Binge Eating Disorder OPNT001 Cocaine Use Disorder Phase I Phase II Phase III NDA Partner FDA Approved Commercialized OPNT001 Bulimia Nervosa OPNT002 Undisclosed Disorder ✔ *as of September 2016

  11. Slide 11: Opioid Overdose

    Opioid Overdose @ Opiant pe "1

  12. Slide 12: People can stop breathing if they overdose from any opioid

    People can stop breathing if they overdose from any opioid, including heroin, fentanyl and opioid painkillers 12 Opioid Overdose • Inappropriate prescribing • Abuse of prescription opioids • Use of illicit opioids Overdose of opioids removes the drive for breathing More deaths occur in the US from o

  13. Slide 13: The opioid overdose epidemic driven by widespread prescribing and abuse of painkillers

    The opioid o verdose e pidemic h as been d riven by widespread prescribing and abuse of opioid p ainkillers 13 All Opioids 25,000 20,000 15,000 10,000 5,000 0 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Rx Opioid Pain Relievers Heroin Y ears D eaths The majority of ove

  14. Slide 14: Naloxone saves lives if given quickly

    14 Naloxone saves lives if given quickly However: only trained personnel able to deliver injectable form, which delays lifesaving treatment Timing is Everything: Understanding the Urgency to Respond Quickly Dial 911 Await ambulance Patient already stopped breathing Help often arrives too late Opioid

  15. Slide 15: NARCAN Nasal Spray has several advantages over injectable naloxone

    15 Opiant’s NARCAN ® Nasal Spray has several a dvantages over i njectable n aloxone and nasal s pray k its Improvised Nasal Kits Injectable Naloxone Autoinjectors • O nly trained personnel • Prep time • N eedles • Very expensive • Needles • Assembly • Not FDA approved • No data • Training • Excellen

  16. Slide 16: NARCAN Nasal Spray achieves equal treatment levels compared to injectable

    16 Opiant’s NARCAN® Nasal Spray achieves equal treatment levels compared to injectable and is easier to administer Time Post Administration (hour) Naloxone Concentration (ng/ml) Dose 3 – 0.4mg Intramuscular Dose 1 – 4mg Intranasal Dose 2 – 2mg Intranasal 6.0 5 .0 4.0 3.0 2.0 1.0 0 .0 0 .0 0.5 1.0 1.

  17. Slide 17: NARCAN Nasal Spray licensed to Adapt Pharma and FDA approved Nov 2015

    NARCAN® Nasal Spray NARCAN® Nasal Spray licensed to Adapt Pharma and FDA approved Nov 2015 17 Key Financial Terms Adapt Pharma Limited » FDA Approved November 18, 2015 » Competitor rejected » Issued IP » $55M potential milestone payments » Up to double - digit royalties » Previous AZUR Pharma founde

  18. Slide 18: Potential $2B addressable market in U.S.

    18 Over 20 million unique opioid users resulting in a potential $2B addressable market in U.S. * Opiant estimate of average selling price 0.1M First Responder Vehicles 1M Opioid Abusers 20M Prescription Opioid Users x $100 per pack* = ~$2B Addressable Market

  19. Slide 19: Binge Eating Disorder

    Binge Eating Disorder @ Opiant pe 19

  20. Slide 20: Binge eating disorder is a common medical problem

    » Part of DSM - 5 » Associated with significant physical and psychological problems » Food and food “cues” activate brain reward system 20 Binge eating d isorder (BED) is a common m edical p roblem… » Shire’s Vyvanse®: only drug approved (2015) - $300M peak US sales forecast » …new regulatory path f

  21. Slide 21: Nasal naloxone data shows promise for Binge Eating Disorder

    164.8 171.3 174.8 179.9 188.6 199.9 0 - 40 - 80 - 120 - 160 - 180 Base 1 - 20 - 60 - 100 - 140 2 3 4 5 6 Opiant’s nasal naloxone data s hows p romise for B inge Eating Disorder 21 Phase IIa POC study ( Helsinki) » 127 patients » Randomized , double blind, placebo controlled » Significant reduction i

  22. Slide 22: Cocaine Use Disorder

    Cocaine Use Disorder @ Opiant pe 22

  23. Slide 23: The challenge of cocaine use disorder: no approved medication

    23 The challenge of cocaine u se d isorder – no a pproved m edication » 1.5M current cocaine abusers in U.S. » Chronic cocaine exposure activates opioid and dopamine reward circuitry » Treatment is limited to behavioral interventions, with limited efficacy and high relapse rates » No FDA approved tr

  24. Slide 24: Novel functional MRI study underway in cocaine patients

    24 Novel functional MRI s tudy u nderway in c ocaine p atients » Funded by NIDA » Nasal opioid antagonist » Collaboration with University of Pennsylvania » 12 patients » Record brain response to visual cocaine cues using fMRI +/ - treatment

  25. Slide 25: Prospective key milestone events

    Prospective key m ilestone e vents Cocaine Addiction Eating Disorders Opioid Overdose 25 4Q15 NARCAN ® Nasal FDA approval 1Q16 First commercial sale NARCAN ® Nasal 4Q16 Formal evaluation of nasal formulation with novel excipient 4Q15 NIDA and UPenn collaboration 4Q16 UPenn interim study results 4Q16

  26. Slide 26: Management

    Arvind Agrawal Executive Vice President, Medical Affairs Management 26 Dr. Roger Crystal Chief Executive Officer Kevin Pollack, Esq. Chief Financial Officer Dr. Michael Sinclair Chairman Dr. Mark Ellison Executive Vice President, Development, Manufacturing and Quality

  27. Slide 27: Treatments for Substance Abuse, Addictive and Eating Disorders

    TREATMENTS FOR SUBSTANCE ABUSE, ADDICTIVE AND EATING DISORDERS 27 September 2016 401 Wilshire Blvd, 12th Floor, Santa Monica CA 90401 O: 1 (424) 252 4756

Opiant Pharmaceuticals — Investor Presentation (September 2016) on 6ix